【摘要】 钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)作为一种新型降血糖药，因其能够降低主要不良心血管事件的发生率，改善肾脏结局，降低心力衰竭住院率和死亡风险而备受关注。然而，SGLT2i并非在所有心血管事件中均获益，例如其对于总体人群的心肌梗死发生率影响并不显著，对卒中风险也没有影响。一个有趣的假设是，SGLT2i对心血管危险因素的影响能力可能有限，尤其是对血脂代谢的作用。虽然目前关于SGLT2i对血脂的影响仍存在争议，但绝大多数研究表明，服用该药物后，总胆固醇、低密度脂蛋白胆固醇和高密度脂蛋白胆固醇均有所升高，而甘油三酯降低。因此，现主要结合相关研究，讨论SGLT2i对糖尿病患者血脂代谢的影响及其可能带来的临床意义。更多还原

【Abstract】 Sodium-glucose cotransporter 2 inhibitor(SGLT2i),novel hypoglycemic agents, have attracted attention for their ability to reduce the incidence of major adverse cardiovascular events, improve renal outcomes, and reduce the risk of heart failure hospitalization and death.However, SGLT2i do not benefit all cardiovascular events, for example, their effect on the incidence of myocardial infarction in the overall population was not significant, nor did they have an effect on stroke risk.An interesting hypothesis is that SGLT2i may have a limited ability to influence cardiovascular disease risk factors, particularly with regard to their effects on lipid metabolism.Although there is still controversy regarding the effects of SGLT2i on plasma lipids, the vast majority of studies have shown an increase in total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol, and a decrease in triglycerides after administration of the drug.Therefore, based on relevant studies, this article mainly discusses the effects of SGLT2i on lipid metabolism in diabetic patients and their potential clinical implications.更多还原